MedTrace Logo

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

NCT05040984 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-03-29

No results posted yet for this study

Summary

A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

Solifenacin Oral Tablet

Solifenacin 1 tablet per day

DRUG

Mirabegron 25mg

Mirabegron 1 tablet per day

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05040984 on ClinicalTrials.gov